[Pulmonary fibrosis following instillation of mitomycin C in the urinary bladder].
Intravesical prophylaxis against recurrence of bladder carcinomas using mitomycin C has proved to be an effective treatment with few side effects. No side effects involving the lungs have so far been observed with systemic administration; with intravesical use, however, this is not the case. We report a 32-year-old man in whom pulmonary interstitial fibrosis occurred after intravesical instillation of mitomycin C. The clinical picture, including the therapy, and the differential diagnosis and practical consequences are all discussed.
D000283:Administration, Intravesical; D000328:Adult; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D006801:Humans; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects* / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D008937:Mitomycins; D016685:Mitomycin
Lungengerüsterkrankungen nach Instillation von Mitomycin C in die Harnblase.